Genaera Announces Patent Issued for Interleukin-9 Receptor.
"This further strengthens our patent portfolio for methods to treat interleukin-9 related conditions," noted Roy C. Levitt, M.D., President and Chief Executive Officer.
Genaera is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Research and development efforts are focused on anti-angiogenesis and respiratory diseases. Genaera has three products in development addressing substantial unmet medical needs in major pharmaceutical markets. These include squalamine, an anti-angiogenesis treatment for eye disease and cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN, a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Nov 1, 2003|
|Previous Article:||Innovative Biosensors licenses biosensor technology from MIT.|
|Next Article:||Reliant acquires Abbott's antiarrhythmic.|